COT Report for the Week Ended April 12: Commercial Signal Failure Looms?
Source: Michael Ballanger  (4/17/16)
Precious metals expert Michael Ballanger dissects Friday's COT report. More >

The Canadian Shield Could Host the Next Bonanza Discovery: Eric Lemieux
Source: Patrice Fusillo of The Gold Report  (4/14/16)
Gold supply is getting tighter, deposits of quality are getting rarer and the project development timeline is getting longer. Enter Canada. The Canadian Shield still offers the possibility of break-out discoveries, says PearTree Securities analyst Eric Lemieux. The recent spate of M&A activity points to the potential of the region, and Lemieux discusses several companies that are well positioned to add value. More >

Deutsche Bank Silver Settlement: GATA Vindicated
Source: Michael Ballanger  (4/14/16)
Precious metals expert Michael Ballanger riffs on the news that Deutsche Bank is settling U.S. silver pricing litigation. More >

Drug Pricing, Presidential Politics, and Three Biotechs with Promise
Source: George S. Mack of The Life Sciences Report  (4/13/16)
While the vagaries of the 2016 political season create uncertainty in the biotech and pharmaceutical sectors, companies are moving ahead with innovative cell therapies, gene therapies and new, safer ways to deliver addictive drugs, and investors find themselves in a position to play the development ideas with varying degrees of risk. In this interview with The Life Sciences Report, George Zavoico of Jones Trading Institutional Services explores how the presidential race could affect the biotech industry, and explains the growth prospects of three biotech names that could strike gold. More >

How Altius Minerals Is Taking Advantage of Market Weakness
Source: Adrian Day  (4/11/16)
Despite the bear market in resources, Altius Minerals has continued to make progress, according to Adrian Day of Adrian Day Asset Management. Day explains why the company remains one of his firm's top core holdings, and why more opportunities lie ahead. More >

Long and Intermediate Trends Crushing Commercials…
Source: Michael Ballanger  (4/8/16)
Precious metals expert Michael Ballanger discusses the tug-of-war going on between the Japanese yen and the U.S. dollar/Chinese yuan, and its effect on precious metals. More >

How Three Companies Have Been Resurrected from Failed Clinical Trials: George Zavoico of JonesTrading
Source: George Mack of The Life Sciences Report  (4/6/16)
Data can create or destroy the value of a biotech investment in an instant, but hitting or missing an endpoint doesn't always tell the story. For instance, Genentech's Herceptin (trastuzumab) is a blockbuster, bringing in $7.4B in revenue during 2015, but at one point investigators thought it was a complete failure. It took patience, time, additional capital and careful analysis of subpopulations of breast cancer patients to figure out that Herceptin would ultimately save many lives. In this interview with The Life Sciences Report, George Zavoico of JonesTrading Institutional Services discusses the growth prospects of three biotech names that have been wrecked and left for dead, but could ultimately resurrect themselves from a misleading pile of rubble.
More >

Jack Chan Sees New Major Buy Signal for Gold But Is Patient
Source: Jack Chan for The Gold Report  (4/6/16)
Technical analyst Jack Chan has examined the charts and says the gold sector is on a new major buy signal, which could signal a new bull market. But he is patiently waiting for confirmation. More >

Stellar Biotechnologies: Cures for Cancer, Alzheimer's Disease, Lupus, and More Underscore the Critical Need to Protect Oceans
Source: Staff of The Life Sciences Report  (4/5/16)
Frank Oakes, the chairman, president and CEO of Stellar Biotechnologies, has a passion for the potential life-saving cures the ocean may provide. His company, a world leader in the production of sustainable, scalable and fully traceable GMP-grade KLH protein, has established research and manufacturing facilities along the Pacific Ocean to produce KLH, and Oakes himself has more than three decades of management experience in aquaculture. In this interview with The Life Sciences Report, Oakes talks about how he got involved in this exciting and emerging space, and describes the potential Stellar KLH has in the burgeoning field of immunotherapy. More >

BonTerra Resources Delivers Its Own March Madness
Source: Thibaut Lepouttre of Caesars Report exclusively for Streetwise Reports  (4/4/16)
BonTerra Resources stock is up just over 70% in March and 146% in 2016. In March, BonTerra acquired nearly 1 Moz of gold at the Larder project and released great drill results on the Gladiator project, and there is more to come. Caesar's Report's Thibaut Lepouttre discusses the merits and effects of such a busy month. More >

Epic Battle Rages on: 'Ali-Frazier' in the Crimex Pits. . .
Source: Michael Ballanger  (4/1/16)
The battle raging between the Bullion Banks and Gold Speculators is every bit as spectacular as the Ali-Frazier fights of the 1970s, says precious metals expert Michael Ballanger. More >

The Gold-to-Silver Ratio: A Truly Generational Opportunity
Source: Michael Ballanger  (3/31/16)
Precious metals expert Michael Ballanger says that owning silver versus owning gold is a high-probability trade that could be the 2016 Trade of the Year.

More >

Diffusion Pharmaceuticals Takes Aim at Brain Cancer: CEO David Kalergis
Source: George S. Mack of The Life Sciences Report  (3/30/16)
It takes extraordinary dexterity to execute a strategic merger, and then to take first steps toward positioning a new molecular entity for a Phase 3 drug trial and potential partnership with a big pharma. That's exactly the inflection point at which Diffusion Pharmaceuticals Inc. finds itself, says CEO David Kalergis. In this interview with The Life Sciences Report, Kalergis lays out Diffusion's plan for pivotal development of its treatment for primary brain cancer, which could drive the company's market cap to valuations that would bring huge upside to investors if successful. More >

Moseda Joins Telus and Apple in the $20B Patient Home Monitoring Sector
Source: Special to The Life Sciences Report  (3/29/16)
Because chronic conditions are difficult to manage by patients at home, with complications, hospitalizations and other expensive interventions sometimes necessary, they account for more than 75% of healthcare costs worldwide. To meet this need, Moseda Technologies has developed innovative, secure mobile software solutions for the $20 billion community/home care market. In this interview with The Life Sciences Report, Moseda's CEO, Dr. Lisa Crossley, describes the company's comprehensive hardware and software solution, dubbed CareKit, which allows patients to receive high-quality care in the home, improving health outcomes and enhancing quality of life for patients and families while reducing the cost of care. More >

Newmarket Gold's Shares Up 75% in 2016 and That Is Just the Beginning
Source: Paul Guedes of The Gold Report  (3/29/16)
Newmarket Gold's shares have appreciated 75% since the beginning of 2016, but CEO Douglas Forster believes that is just the beginning. The company's storied founders have set their sights on making Newmarket the next high-quality mid-tier gold producer. In this interview with The Gold Report, Forster puts forth his vision of how, starting with the acquisition of Crocodile Gold, he will make that happen. More >

VANC Pharmaceuticals Could Earn 75% Net Margin with OTC Iron Supplement
Source: Nick Hodge, Outsider Club  (3/28/16)
On March 7, VANC Pharmaceuticals announced the launch of a new over-the-counter (OTC) iron supplement called Hema-Fer. As the company gears up to market Hema-Fer across Canada, it is important to understand that VANC sells two types of products: generic prescription drugs and over-the-counter products. More >

Marc Faber: Gold Still Most Desirable Currency in Wake of Brussels Attack
Source: The Gold Report Staff  (3/28/16)
After several years of low gold prices, 2016 has brought a rebound, with the metal rising almost 20% since the first of the year, although recent price corrections have slowed gold's advance. After the Brussels terrorist attacks last Tuesday, gold rose briefly, but then was undercut by a strong U.S. dollar rally. Investors are wondering whether gold is in a temporary correction mode or if the three-month bull has run its course. Marc Faber and other experts weigh in. More >

Gold Royalty Companies Continue to Progress
Source: Adrian Day  (3/28/16)
The large gold royalty companies remain among our top holdings, notwithstanding the high valuations and our comments on the overall gold market and short-term concern on the gold stocks. More >

Gold: Correction Ahead, But Market Very Strong
Source: Adrian Day  (3/25/16)
Gold is up over 15% this year so far, while the gold stocks (per XAU index) have risen over 50%. But investors are skeptical about this year's gold rally, and that's a good thing. For the past several years, we have seen strong rallies in gold and gold stocks early in the year, only to see the market reverse and end the year down. Investors are reluctant to jump on board this year's rally. More >

Reservoir Minerals Has Many Options to Enhance Value
Source: Adrian Day  (3/24/16)
Reservoir Minerals Inc. (RMC:TSX.V) has moved up sharply this month—over 50%—after Lundin Mining Corp. (LUX:TSX) made an offer to buy part of Freeport-McMoRan Copper & Gold Inc.'s (FCX:NYSE) interest in its joint venture with Reservoir. But it remains a strong buy. More >

How to Trade Sarepta Therapeutics Ahead of ADCOM: Chen Lin
Source: Chen Lin, What Is Chen Buying? What Is Chen Selling?  (3/24/16)
Sarepta Therapeutics Inc. (SRPT:NASDAQ) is scheduled to have its FDA Advisory Committee Meeting (ADCOM) to review eteplirsen as a treatment for Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping on April 25, a little over a month from now. According to newsletter writer Chen Lin, this is a huge binary event for the company. In this article, Lin lays out his investment thesis on the stock ahead of the meeting, and his hopes for eteplirsen's approval. More >

Nobilis Health Doubles Down, Offering Organic Growth and Aggressive Acquisitions: Kolin Ozonian
Source: George S. Mack of The Life Sciences Report  (3/23/16)
Businesses can grow in two ways—internally and externally. Nobilis Health Corp. has a voracious appetite for both. The company is a development and management firm that acquires private outpatient surgical centers—in short, it's a business model built on efficiencies. Nobilis scans the market for clinics that can be acquired and scaled up using sophisticated direct marketing approaches. In this interview with The Life Sciences Report, Nobilis' mergers-and-acquisitions specialist Kolin Ozonian talks about the business model and tells investors how he and the Nobilis team plan to aggressively grow the company. More >

Cellceutix Pipeline Continues to Hit Milestone After Milestone
Source: Staff of The Life Sciences Report  (3/23/16)
Cellceutix Corp. (CTIX:OTCMKTS), a small-cap biotech company focused on developing novel compounds for a range of applications, has released a flurry of announcements over the past five weeks as several of its pipeline drugs cleared regulatory hurdles and readied for their next milestones. The series of press releases on three different Cellceutix experimental drugs put a charge in the stock, sending it upward in a matter of a few days by more than 57% to a high of $1.81/share on Tuesday, March 21. More >

Ominous Response to Brussels Torpedoes Precious Metals Rally…
Source: Michael Ballanger  (3/23/16)
Michael Ballanger discusses the effect of events in Brussels on precious metals. More >

Sumitomo's Quest for Gold Starts with Viscount Mining
Source: Gwen Preston, Resource Maven  (3/21/16)
Japanese giant Sumitomo Corporation is on a quest for gold. Its only exploration-level joint venture is with Viscount Mining. Resource Maven Gwen Preston explores the Viscount proposition, including the historic potential of its Cherry Creek, Nevada, land package and its potential to produce Carlin-type gold. More >